drugset / Trial / NCT05483868
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.
Timeline
- Start
- 2022-09-26
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belzupacap Sarotalocan | Protein / enzyme biologic | 50 ug | Other |
| Subject | Belzupacap Sarotalocan | Protein / enzyme biologic | 100 ug | Other |
| Subject | Belzupacap Sarotalocan | Protein / enzyme biologic | 200 ug | Other |
| Subject | Belzupacap Sarotalocan | Protein / enzyme biologic | 400 ug | Other |
| Subject | Belzupacap Sarotalocan | Protein / enzyme biologic | 800 ug | Other |